Abstract：Objective: To analyze the clinical curative effect and side effects of 1 470 nm diode laser combined with intravesical chemotherapy of apaziquone for superficial bladder tumor. Methods: Fifty patients with superficial bladder tumor were randomly divided into a group of 1 470 nm diode laser combined with intravesical chemotherapy of apaziquone (combination group) and a group of 1 470 nm diode laser combined with intravesical chemotherapy of pirarubicin (control group). After treatment, the patients in two groups were followed up for 36 months, and the tumor recurrence rate, recurrence-free survival time and adverse reactions of chemotherapy were compared between the two groups. Results: The one-year recurrence rate in the combination group and control group was 5.36% (3/56) and 19.64% (11/56) respectively, and the 36-month cumulative recurrence rate in the combination group and control group was 8.93% (5/56) and 26.79% (15/56) respectively. The one-year recurrence rate and the 12-36 month cumulative recurrence rate in the combination group were significantly lower than those in the control group (P<0.05). No statistically significant difference was observed in side effects between the combination group and control group (P>0.05). Conclusions: 1 470 nm diode laser combined with intravesical chemotherapy of apaziquone for superficial bladder tumor is superior to 1 470 nm diode laser combined with pirarubicin. The apaziquone can decrease recurrence rate, at the meantime, the side effects are easily to be tolerated, and it is worthy of wide clinical application.
